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A running title 
  Availability of serum levels of PD-L1 and B7-H4 
 
Novelty and Impact statements 
  PD-L1 and B7-H4 are negative regulators of T-cell-mediated antitumor response. 
Clinical impact of serum levels of the B7 molecular family remains unclear in renal cell 
carcinoma (RCC). This study shows that higher preoperative serum levels of PD-L1 and 
B7-H4 are associated with invasive and metastatic potential of the tumors, a poor 
response to VEGF-targeted therapy and an unfavorable prognosis, indicating that 
investigating the preoperative serum levels of B7 family molecules may assist in the 
design and patient selection strategies of not only VEGF-targeted therapy but also clinical 
trials of immune checkpoint therapy targeting PD-1/PD-L1 axis. 
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Abstract 
  Renal cell carcinoma (RCC) is an immunogenic and proangiogenic cancer. Although 
anti-vascular endothelial growth factor (VEGF) therapies achieve impressive responses 
in some patients, many tumors eventually develop resistance to such therapy. The B7 
family molecules such as CTLA-4, PD-1, and PD-L1 are pivotal players in immune 
checkpoints that positively or negatively regulate various immune responses. Recently, 
immunotherapy based on blocking immune checkpoints with anti-CTLA4, anti-PD-1, or 
anti-PD-L1 antibodies has been proposed as a potential new approach to the treatment of 
metastatic RCC. Higher expression of PD-L1 and B7-H4 in the tumors is associated with 
a poor prognosis in RCCs, however, the clinical impact of serum levels of B7 family 
molecules has not been elucidated in patients with metastatic RCCs receiving 
VEGF-targeted agents. We assessed the preoperative serum levels of B7 family 
molecules, including CD80, CD86, PD-1, PD-L1, B7-H3, B7-H4, and CTLA-4, and 
CD28 in RCC patients, and determined their relations with various clinicopathological 
characteristics. Elevated preoperative serum levels of PD-L1 and B7-H4 were correlated 
with less differentiated tumors, higher invasive and metastatic potential, a worse response 
to anti-VEGF therapy, and shorter overall survival. These findings suggested that 
investigating preoperative serum levels of PD-L1 and B7-H4 might not only be useful to 
assess the biological aggressiveness of RCCs, but also to predict the efficacy of 
anti-VEGF therapy and the eventual prognosis, indicating the future design of clinical 
trials of therapies targeting immune checkpoint in advanced RCCs. 
 
 
 
 
 
 
Introduction 
 
  The incidence of renal cell carcinoma (RCC) is steadily increasing and it now accounts 
for 2-3% of all adult malignancies.1 About 40% of RCC patients die of metastatic disease, 
because metastases are often present at diagnosis and relapse following nephrectomy is 
common.2 Although localized RCC can be cured by surgery, the prognosis is poor if 
distant metastases have developed. Approximately 30% of RCC patients have metastatic 
disease at presentation and recurrence occurs in another 30% of patients after complete 
resection of the primary tumor.2 
  Clear cell RCC (ccRCC) is a typical immunogenic tumor. It frequently contains high 
levels of tumor-infiltrating T cells and cytotoxic T cells that recognize and selectively kill 
tumor cells, and tumor-specific T cells can be detected in the blood of RCC patients.3-5 
Cytokines secreted by tumor cells or host cells play an important role as mediators and/or 
regulators of various tumor-host interactions involved in the progression of malignancy. 
T cells have an important role in the host immune response to malignancies, which is 
most evident in the case of tumors treated by immunotherapy. Cytokines are required for 
the proliferation and differentiation of effector T cells (Teff) and regulatory T (Treg) cells, 
and activation and suppression of the immune system show dynamic interaction, with 
various cytokines exerting effects in either direction and even doing so simultaneously. 
Thus, while immunocytokine therapy was the mainstay of ccRCC treatment for a long 
time, its effectiveness was extremely limited. 
  However, improvements in understanding of the molecular pathways involved have 
revealed that ccRCC is characterized by high constitutive production of vascular 
endothelial growth factor (VEGF) that induces a specific tumor vasculature. After the 
introduction of targeted therapy has dramatically changed the treatment available for 
metastatic RCC and has improved the progression-free survival of patients by months 
with this disease.6 However, many tumors eventually develop resistance to targeted 
therapy, and only a very small minority of patients remains alive at 5 years due to 
secondary mutation of the target protein or compensatory changes within the target 
pathway that bypass the site of inhibition.7 Accordingly, there has been increasing 
interest in new immunotherapy modalities that diverge from this paradigm and could 
potentially improve the outcome of patients with metastatic RCC, including 
anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibody and 
anti-programmed cell death 1 (PD-1)/PD-ligand 1 (PD-L1) antibody.8 
  Tumor cells need to evade destruction by the immune system to survive and this is now 
viewed as one of the “hallmarks of cancer”.9 Recent improvements in our understanding 
of tumor progression have shed light on new options for immunotherapy. Important 
insights into the limitations of T cell-based anticancer immunotherapy have been 
provided by the discovery of inhibitory pathways termed immune checkpoints (a plethora 
of inhibitory pathways that are crucial for maintaining self-tolerance and modulating the 
duration and amplitude of physiological immune responses), and it has been found that 
tumors co-opt certain immune checkpoint pathways as a major mechanism of immune 
resistance.10 Accordingly, the blockade of such immune checkpoints may be a promising 
approach to the activation of antitumor immunity. The B7 and CD28 families play pivotal 
roles in the immune checkpoint system by activating and inhibiting co-stimulatory 
molecules that positively or negatively regulate immune responses.11,12 Aberrant 
expression of co-inhibitory molecules from the B7 family has been associated with 
reduced antitumor immunity and with immune evasion, prompting the development of 
therapeutic agents that can restore T cell function. Clinical studies investigating the 
effects of blocking CTLA-4 and PD-1/PD-L1 have yielded exceptionally promising 
results in patients with advanced melanoma and other cancers, including RCC.8 However, 
the role of B7 family molecules in human cancers, including RCC, has been investigated 
by using tissue samples up to now. Since obtaining blood samples from patients is easier 
than harvesting tissue by biopsy, circulating biomarkers rather than tissue markers would 
be useful for assessing the evolution of tumor and immune responses during therapy, as 
well as for individualized adjustment of treatment. Therefore, we were interested in 
measuring the serum levels of B7 family molecules and CD28 family receptors in 
patients with ccRCC. We investigated the preoperative serum levels of B7/CD28 
molecules simultaneously in ccRCC patients and to assess correlations with 
clinicopathological features and the response to treatment. Such information should shed 
light on the role and biological significance of immune checkpoints in human ccRCCs. 
 
Materials and Methods 
Patients 
  This is a retrospective study to investigate the preoperative serum levels of B7/CD28 
molecules of the 181 patients (109 men and 72 women) in whom ccRCC was diagnosed 
histopathologically and nephrectomy was performed at our centers between June 2007 
and June 2014. Radical nephrectomy for 118 non-metastatic patients (cTanyNanyM0) or 
cytoreductive nephrectomy for 63 metastatic patients (cTanyNanyM1) were performed 
before any other therapy. All of them underwent preoperative imaging (CT and/or MRI) 
for tumor staging. The postoperative follow-up period ranged from 3 to 100 months 
(median: 31 months). The tumor grade and clinical stage were determined according to 
the Fuhrman system and the TNM classification, respectively.13,14 In this cohort, the 
study identified 63 patients with metastatic ccRCC (cTanyNanyM1) at diagnosed who had 
underwent cytoreductive nephrectomy and received interferon (IFN) alpha or tyrosine 
kinase inhibitors for metastatic lesions as adjuvant therapy. This study was conducted in 
accordance with the Helsinki Declaration and was approved by the institutional ethical 
review board of Dokkyo Medical University Hospital. Each patient signed a consent form 
that was approved by our institutional Committee on Human Rights in Research. 
  To be included in the study, patients were required to (1) be adults (≥18 years old) 
diagnosed with ccRCC; (2) be treated for 63 metastatic ccRCC at cytoreductive 
nephrectomy with sunitinib as first-line therapy; (3) have discontinued the first agents for 
medical reasons (e.g., disease progression, non-response without progression, drug 
intolerance); (4) have subsequently initiated axitinib as second-line therapy in ; and (5) 
have their medical records available for review for the entire period encompassing 
initiation from first therapy until the most recent follow-up or death. Postoperative 
adjuvant therapy with sunitinib was given to 63 patients (initial dose of 37.5 or 50 mg/day, 
four weeks on and two weeks off), as first-line systemic therapy after cytoreductive 
nephrectomy. Within the patients refractory to first-line sunitinib, the 40 patient received 
axitinib (recommended starting dose of 10 mg/day) as second-line therapy. Progression 
was determined by physicians based on radiographic evidence indicating progression of 
tumor lesions or occurrence of new lesions, physical exams indicating worsening 
performance status, or cancer-related symptoms (e.g. increased pain, fever and weight 
loss). Doses of sunitinib and axitinib were decreased if grade 3/4 toxicity occurred. The 
effect of treatment on the tumors was assessed according to RECIST criteria.15 The final 
date of assessment of the disease was collected from patient medical records in 
September 2015. 
  Serum samples obtained from the 181 ccRCC patients and 25 healthy controls (14 men 
and 11 women aged 22-73 years) were stored at 80C until analysis. The serum levels of 
B7 family molecules, CD28, and VEGF were measured by using the following ELISA 
kits: human CD80 (CSB-E15768h, Cusabio Biotech, China), human CD86 
(CSB-E08542h, Cusabio Biotech), human B7-H4 (CSB-E15013h, Cusabio Biotech), 
human PD-1 (CSB-E13643h, Cusabio Biotech), human PD-L1 (CSB-E13644h, Cusabio 
Biotech), human CD28 (CSB-E09296h, Cusabio Biotech), human B7-H3 (DB7H30, 
R&D Systems, MN), human VEGF (DVE00, R&D Systems, MN), and human CTLA-4 
(KA0165, Abnova, Taiwan), as described previously.16 The mean value for three blood 
samples was used. 
Statistical analysis 
  Baseline characteristics were compared using Wilcoxon rank-sum tests for continuous 
variables and chi-square tests for categorical variables. Regarding the relationship 
between preoperative serum levels and variables, statistical analysis was performed by 
using the Mann-Whitney U test to compare two groups and the Kruskal-Wallis test for 
comparisons among three or more groups. Spearman's rank correlation coefficient 
analysis was employed to determine the relations between levels of the molecules of 
interest. Cause-specific survival curves were drawn for the ccRCC patients by the 
Kaplan-Meier method and differences of survival were examined by the log-rank test. 
The impact of T cell regulatory molecules, tumor grade, pT stage, pN stage, microscopic 
vascular invasion, and distant metastasis (M stage) on survival was assessed by Cox 
proportional hazards analysis using univariate and multivariate models. In all analyses, a 
P value < 0.05 was considered to indicate significance. Data were analyzed with 
commercially available software, as described previously.16 
 
Results 
Preoperative serum levels of B7 family molecules, CD28, and VEGF  
  The preoperative serum levels of B7-H4, PD-L1 and VEGF were significantly higher in 
ccRCC patients than in the healthy controls (Figure 1 and Table 1), but those of PD-1, 
B7-H3, CTLA-4, CD28, CD80, and CD86 were not (Figure 1, Table 1 and 
Supplementary Table S1). 
  Investigation of the correlations between preoperative serum levels of VEGF and B7 
family molecules or CD28 family receptors in all cases showed that the preoperative 
serum VEGF level was closely associated with that of B7-H4 (r2 = 0.66, Figure 2A) and 
weakly related with that of PD-L1 (r2 = 0.39, Figure 2C), but not with the levels of PD-1, 
B7-H3, CTLA-4, CD28, CD80, and CD86. Within metastatic (M1) cases, preoperative 
serum VEGF level was significantly related with that of B7-H4 (r2 = 0.54, Figure 2B) and 
weakly related with that of PD-L1 (r2 = 0.26, Figure 2D).  
Association of the preoperative serum levels of PD-1, PD-L1, B7-H4, and VEGF 
with aggressive and metastatic RCC 
  The preoperative levels of PD-1, B7-H4, and VEGF were higher in patients with a 
Karnofsky performance status below 80% than in those above 80% (Table 1).  
  Higher preoperative serum levels of PD-L1, B7-H4, or VEGF were related to less 
differentiated tumors, local invasion, regional lymph node metastasis, microscopic 
vascular invasion, and distant metastasis (Table 1).  
  An elevated preoperative serum level of PD-1 was correlated with local invasion and 
microscopic vascular invasion (Table 1). 
  Elevation of serum CD28 was correlated with local invasion and showed a weaker 
relation with microscopic vascular invasion (Supplementary Table S1). 
  Elevation of serum CD80 and CD86 was correlated with less differentiation, local 
invasion, and microscopic vascular invasion (Supplementary Table S1). 
  In contrast, serum levels of CTLA-4 and B7-H3 were not correlated with any of these 
pathological characteristics (Supplementary Table S1). 
Relationship between serum levels of B7 family molecules and the response to 
VEGF-targeted therapy for metastatic ccRCC 
  Sixty-three patients with metastatic disease at cytoreductive nephrectomy received 
sunitinib as first-line adjuvant therapy. Of 63 patients, 36 patients had clinical benefit, but 
27 patients did not. Eleven patients out of latter 27 patients had best supportive care after 
sunitinib. Forty patients received axitinib as second-line therapy; 23 patients showed a 
favorable response, while the other 17 patients did not. The patients with lower 
preoperative serum levels of PD-L1, B7-H4 and VEGF showed a favorable response to 
sunitinib or axitinib (P=0.0216, P=0.0024, and P=0.0382, respectively, Table 1).  
  In contrast, preoperative serum levels of PD-1, B7-H3, CTLA-4, CD28, CD80, and 
CD86 were not associated with the response to treatment (Table 1 and Supplementary 
Table S1). 
Association of PD-L1 and B7-H4 elevation with shorter overall survival in all 
ccRCC patients 
  The median preoperative serum level of PD-L1 was 18.3, so the patients were divided 
into two groups at this cut-off value. Kaplan-Meier analysis showed that a higher PD-L1 
level was associated with shorter overall survival (Figure 3A). Similarly, a higher B7-H4 
level (median: 0.383) and a higher VEGF level (median: 72.6) were also associated with 
shorter overall survival (Figures 3B,C). The levels of PD-1, B7-H3, CTLA-4, CD28, 
CD80, and CD86 were not associated with overall survival. While PD-L1, B7-H4, VEGF, 
less differentiation, local invasion, regional lymph node involvement, microscopic 
vascular invasion, and metastasis were significant according to Cox univariate analysis, 
PD-L1, B7-H4, regional lymph node involvement, and metastasis had impact on shorter 
overall survival according to multivariate analysis (Table 2). 
Elevation of PD-L1 and B7-H4 is associated with early relapse after radical 
nephrectomy in non-metastatic ccRCC patients 
  The 108 patients with cN0M0 tumors at nephrectomy were divided into two groups 
based on the median preoperative serum levels of B7 family molecules, CD28, and 
VEGF. Comparison of the Kaplan-Meier curves for the low and high value groups 
revealed that high levels of PD-L1 (median: 14.4), B7-H4 (median: 0.318), and VEGF 
(median: 41.3) were associated with early relapse after radical nephrectomy (Figure 4), 
while the other molecules did not show any association. Although less differentiation, 
local invasion, microscopic vascular invasion, PD-L1, B7-H4, and VEGF were 
associated with early relapse after nephrectomy according to univariate analysis, only 
PD-L1 and less differentiation were significant by multivariate analysis (Table 3). 
 
Discussion 
  One of the most promising approaches to activating therapeutic antitumor immunity is 
the blockade of immune checkpoints, because it has become clear that tumors utilize 
these checkpoints as a mechanism of resistance, particularly against T cells specifically 
targeting tumor antigens.10 Recent preclinical and clinical studies have demonstrated that 
checkpoint blockade using anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies can be 
successful for cancer immunotherapy.18-20 Therefore, it is important to assess whether T 
cell regulatory molecules can be used as biomarkers to predict tumor resistance and guide 
the choice of therapy, which is why we investigated the preoperative serum levels of B7 
family molecules and CD28 family receptors in RCC patients as well as their associations 
with clinicopatological features.  
  There were four main findings of this study. First, the preoperative serum levels of 
PD-L1, B7-H4, and VEGF in ccRCC patients were significantly higher than those in the 
healthy controls, and the correlation of B7-H4 or PD-L1 with VEGF in ccRCC patients 
was established at their higher expression levels, in particular in metastatic disease, 
indicating that this correlation would have any disease-related implications. Second, the 
preoperative serum levels of PD-1, PD-L1, B7-H4, and VEGF were correlated with the 
invasive and metastatic potential of ccRCC. Third, patients with high preoperative serum 
levels of PD-L1 and B7-H4 showed a poor response to the VEGF-targeted therapy, and 
had shorter overall survival according to multivariate analysis. Fourth, the higher 
preoperative serum level of PD-L1 was associated with early relapse after nephrectomy 
according to multivariate analysis. These findings suggest that the serum levels of 
molecules in the B7 family might be useful for understanding the biological 
characteristics of ccRCC and for predicting the response to the VEGF-targeted therapy 
and the survival. 
  Increased angiogenesis and immune system evasion are two mechanisms which help 
ccRCC to proliferate and metastasize. Although VEGF is primarily known for its role in 
promoting angiogenesis, there is mounting evidence that VEGF also has an 
immunosuppressive effect and that targeting tumor vasculature may increase the efficacy 
of immunotherapy. ccRCC can evade immune surveillance by expressing PD-L1, which 
binds to PD-1 on the surface of activated T and B cells, thus negatively regulating 
immune activity.17 There is a strong association between higher tissue levels of PD-L1 
expression and adverse clinical outcomes of various cancers, including RCC. 11,21-23 Dong 
et al. reported that PD-L1 overexpression by tumors in vivo and in vitro leads to immune 
tolerance, whereas blockade of PD-L1 or PD-1 enhances antitumor immunity.24 
Blockade of the PD-L1/PD-1 interaction achieves a durable response in approximately 
30% of patients with ccRCC, and the response seems to be related to the tumor level of 
PD-L1 expression.18,19 However, it remains challenging to select patients who are likely 
to respond to anti-PD-1/PD-L1 therapy.12 In the COMPARZ trial, RCC patients received 
sunitinib or pazopanib therapy and increased immunohistochemical tumor cell PD-L1 
expression was associated with shorter survival.25 In the present study, higher 
preoperative serum level of PD-L1 was correlated with poorer differentiation, invasive 
and metastasis profiles, and shorter overall survival, and was independent prognostic 
factors for overall survival. Frigola et al. reported that an elevated preoperative level of 
soluble PD-L1 is associated with an increased risk of death from ccRCC, and they 
suggested that release of soluble PD-L1 molecules may be a mechanism by which tumors 
impair systemic antitumor immunity, suggesting that inactivation or removal of soluble 
PD-L1 from the serum could be clinically beneficia.26 Taken together, these findings 
have focused attention on blockade of PD-1/PD-L1 as a possible strategy for antitumor 
immunotherapy in patients with advanced RCC. 
  B7-H4 is a negative regulatory molecule expressed on the cell membrane that inhibits 
proliferation and cytokine production by CD4 and CD8 T cells.11 In general, B7-H4 
positivity is associated with advanced cancer and poor survival, and this is also the case 
for RCC.11,27 In an experimental model of lung metastasis, B7-H4 expression by host 
cells was demonstrated to suppress tumor-specific T cell responses and promote the 
infiltration of immunosuppressive T cell subsets into the lungs. As a result, B7-H4 WT 
mice had more lung metastases than B7-H4 knockout mice.28 Expression of B7-H4 was 
also reported to show a correlation with tumor infiltration by Treg cells.29 
Tumor-infiltrating lymphocytes may be a manifestation of antitumor immunity, but 
increased tumor infiltration by T cells is associated with shorter survival of RCC patients, 
4 indicating that there is a potential for the mechanisms of T cell immunity to fail in RCC. 
Zhang et al. recently reported that B7-H4 contains a functional nuclear localization 
sequence (NLS), which is responsible for the nuclear localization of this molecule in 
human RCC tissues.30 They also reported that a point mutation of the B7-H4 NLS motif 
suppressed leptomycin B - induced nuclear accumulation of B7-H4 and abrogated 
B7-H4-mediated proliferation and cell cycle progression of HEK293 human embryonic 
kidney cells, while wild-type B7-H4 confers chemoresistance on RCC cell lines, 
indicating that nuclear localization of B7-H4 might be crucial for its influence on cell 
proliferation and cell cycle progression.30 Thompson et al. reported in 101 human RCC 
patients that the higher serum-soluble B7-H4 levels were associated with poorer 
differentiation, local invasion, lymph node metastasis and distant metastasis.31 Zhang et 
al. reported in 93 human hepatocellular carcinoma (HCC) patients that soluble B7-H4 
levels in patients were significantly higher than that in healthy controls; high sB7-H4 
levels were correlated with tumor differentiation, tumor invasion, tumor-node metastasis 
stage, and poor overall survival; high sB7-H4 levels were independent prognostic factors 
for overall survival.32 These findings are consistent with our observation in RCCs in this 
study. Thus, serum levels of B7-H4 may be potential diagnostic and prognostic marker. 
Taken together, these observations provide a basis for targeting B7-H4 in cancer and 
B7-H4 is thus believed to have potential as a biomarker. Furthermore, given the Cox 
multivariate analyses in which PD-L1, B7-H4, regional lymph node involvement, and 
metastasis had significant impact on shorter overall survival, it might be possible to 
provide a better prognostic model using PD-L1, B7-H4 with either lymph node status or 
metastatic status for ccRCC patients. Similarly, since PD-L1 and differentiation were 
significant for recurrence-free survival, preoperative serum level of PD-L1 and 
histological grade might be available for predicting recurrence in N0M0 cases after 
nephrectomy.  
  VEGF is a master regulator of angiogenesis, and also has profound effects on immune 
regulatory cell function, specifically inhibiting dendritic cells (DC) maturation and 
antigen presentation. For many tumors, hypoxia causes tumor cells, stromal cells, and 
normal cells to produce VEGF with immunosuppressive effects both locally and at 
distant sites, and creates a microenvironment of inhibitory inflammatory cells; the 
recruitment of myeloid-derived suppressor cells (MDSC) and the induction of Treg cells 
by inhibiting DC maturation.33-35  
On the other hand, it is not clear that PD-L1, B7-H4 and VEGF could evade immune 
surveillance in the cooperative or independent manner by negatively regulating the 
immune system in ccRCC, and whether VEGF is the causal factor in release of PD-L1 or 
B7-H4 expressed by RCC to peripheral blood. In the present study, the preoperative 
serum VEGF level was associated with that of PD-L1 and B7-H4, and higher 
preoperative serum levels of PD-L1, B7-H4, or VEGF were related to less differentiated 
tumors, local invasion, regional lymph node metastasis, microscopic vascular invasion, 
and distant metastasis. Therefore, we hypothesize that tumors with increased VEGF 
expression would possess an immunosuppressive tumor microenvironment and 
tumor-derived PD-L1, B7-H4, and VEGF may locally inactivate immune cells. However, 
as Frigola et al. suggested, systemic effects either by recirculation of immune cells 
through PD-L1, B7-H4, and VEGF–positive tumor sites or by the release of biologically 
active soluble forms of PD-L1, B7-H4, and VEGF into the circulation cannot be excluded, 
indicating that both scenarios can contribute to global immunosuppression.26  
  In contrast, the preoperative serum levels of CTLA-4, B7-H3, CD28, CD80, and CD86 
were not correlated with tumor biological characteristics in the present study. CTLA-4 is 
a member of the immunoglobulin gene superfamily and is a B7-binding protein along 
with its homologue (CD28).11 It plays an important role in downregulation of T cell 
responses, T cell homeostasis, and maintenance of peripheral tolerance. A CTLA-4 
antibody was the first member of this class of immunotherapy agents to receive US FDA 
approval, and it achieved promising results in a recent phase II study of metastatic 
ccRCC.11 CD28 binds CD80 and CD86 expressed by activated antigen-presenting cells 
and plays as the prototypic T cell costimulatory receptor that augments TCR-mediated T 
cell proliferation, survival, metabolic activity, and effector function.10,11 CD80 and CD86 
are homologous costimulatory molecules predominantly expressed on antigen-presenting 
cells. Interaction of these B7 family molecules with CD28 and CTLA-4 expressed on T 
cells is a critical step in T cell activation. Despite their structural similarities, CD80 and 
CD86 make distinct contributions to the development of pathogenic T cells in 
autoimmune diseases and protective T cells in infectious diseases. While B3-H7 shows 
structural similarities to the classical co-stimulatory molecules CD80 and CD86, there 
have been contradictory findings regarding its possible co-stimulatory or co-inhibitory 
role. Thus, the relationship between B7-H3 expression and the prognosis of cancer 
patients remains to be elucidated.  
  The limitations of our study are retrospective design and the present study investigated 
a relatively small number of patients and the follow-up period was too short to draw 
definite conclusions. The findings of our study need further validation in forthcoming 
studies, better in prospective controlled large sampled clinical trials. As biomarkers may 
not be static, serial measurement may be required to assess the evolution of tumor and 
immune responses during therapy, as well as to adjust treatment in a personalized manner. 
In this context, in addition to examination of the expression of PD-L1, B7-H4 and VEGF 
in the primary tumors, repeated measurement of the serum levels of B7 family molecules 
may be important for monitoring both tumor behavior and the condition of patients in the 
prospective studies on a larger scale. If we accept the hypothesis that release of soluble T 
cell suppressor molecules is a mechanism by which tumors interfere with systemic 
antitumor immunity, it is also important to determine whether the serum levels of soluble 
T cell regulatory molecules (such as PD-L1, B7-H4, PD-1, and CTLA-4) can be used as 
biomarkers to predict the effectiveness of immunotherapy targeting T cells in patients 
with ccRCC. Further investigation is needed to evaluate the mechanistic basis of the 
ability to counteract the dual function of angiogenic factors in promoting vessel growth 
and in suppressing immune responses by the parallel effects on host immunity and tumor 
vasculature in ccRCC. It is hoped that further investigation of the role of T cell regulatory 
molecules in promoting tumor immune tolerance will lead to the development of new 
immunotherapy options for ccRCC. 
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Figure Legends 
 
Figure 1: Preoperative serum levels between healthy volunteers and RCC patients.  
   
  Preoperative serum levels of VEGF (A), B7-H4 (B) and PD-L1 (C) were higher in 
RCC patients than those in healthy volunteers, while those of PD-1 (D) were not. The 
median value is the central line, the box is the interquartile range, the bars are the full 
range, and the points are the outliers. Bold circled P values were obtained by comparing 
the two groups with the Mann-Whitney U test. 
 
Figure 2: Relationship between serum B7 family molecules. 
  
  Spearman rank correlation between the preoperative serum levels of VEGF and 
B7-H4/PD-L1 in all 171 cases (A, C) and in 83 metastatic (M1) cases at nephrectomy (B, 
D). The preoperative serum levels of B7-H4 and PD-1 were positively associated with 
those of VEGF in all case and in M1 cases. 
 
Figure 3: Overall survival in all 181 cases. 
 
  This survival curve is based on the median values of preoperative serum levels of B7 
family molecules in all 181 cases. The cases were divided into two groups at this level - 
high and low expression. P value was analyzed by log-rank test. The patients with higher 
preoperative serum levels of PD-L1 (A), B7-H4 (B) and VEGF (C) had poorer overall 
survival. 
 Figure 4: Recurrence free-survival in 108 N0M0 cases at nephrectomy. 
 
  This survival curve is based on the median values of preoperative serum levels of B7 
family molecules in non-metastatic (M0) cases at nephrectomy. The cases were divided 
into two groups at this level - high and low expression. P value was analyzed by log-rank 
test. Higher preoperative serum levels of PD-L1 (A), B7-H4 (B) and VEGF (C) in N0M0 
patients at nephrectomy were associated with shorter recurrence free- survival. 
 
 
 
 
 
